Pancoast Tumor: Metastatic vs. Non-Metastatic

What Is a Pancoast Tumor?

A Pancoast tumor (also called a superior sulcus tumor) is a carcinoma arising in the extreme apex of the lung, involving the parietal pleura or deeper structures overlying the first rib. Chest wall involvement below the second rib is NOT classified as a Pancoast tumor. Most are non-small cell lung carcinoma (NSCLC), typically squamous cell carcinoma, though SCLC and rare non-malignant causes can produce the same syndrome. - Schwartz's Principles of Surgery, 11th Ed.

Pancoast Syndrome (Clinical Triad)

The tumor is defined by its location and what it invades locally. Pancoast syndrome is present in ~one-third of patients with superior sulcus tumors and consists of:

Shoulder/arm pain along the C8, T1, T2 nerve distribution
Horner syndrome - ptosis, miosis, anhidrosis (invasion of paravertebral sympathetic chain and stellate ganglion)
Hand muscle weakness and atrophy (intrinsic muscles, as tumor progresses)

Ulnar nerve distribution pain radiating to axilla and upper back
Destruction of 1st and 2nd ribs (sometimes thoracic vertebrae)
Spinal cord compression/paraplegia if tumor extends through intervertebral foramina
Murray & Nadel's Textbook of Respiratory Medicine; Robbins & Kumar Basic Pathology

Is It Metastatic or Non-Metastatic?

This is the core question. Pancoast tumors can be either, and staging drives all treatment decisions.

Typical Staging Distribution

Most tumors at presentation are locally advanced but non-metastatic:

Stage	Classification	Proportion (MD Anderson series)
IIB	T3 N0 M0	25%
IIIA	T3-4 N1-2 M0	22%
IIIB	T4 or N3 M0	53%
IV	Any M1 (metastatic)	Excluded from surgical series but significant

"It is estimated that one-third to one-half of all superior sulcus tumors have identifiable distant metastasis at diagnosis." - Murray & Nadel's Textbook of Respiratory Medicine

So the majority that present for surgical evaluation are non-metastatic, but a very large proportion of ALL Pancoast tumors (33-50%) are already metastatic at diagnosis.

Non-Metastatic (Locally Advanced)

Staged T3 N0 M0 (Stage IIB) to T4 N3 M0 (Stage IIIB)
Local invasion: chest wall, ribs, brachial plexus, subclavian vessels, vertebral body, paravertebral sympathetic chain
Potentially resectable (Stage IIB/IIIA with negative mediastinum)
Standard treatment: neoadjuvant chemoradiotherapy + surgery

Metastatic (Stage IV)

Distant spread most commonly to: brain (most common relapse site), liver, adrenal glands, bone
Brain is specifically the most common site of relapse even after complete resection of localized disease
Treatment: systemic chemotherapy (with or without targeted therapy based on molecular markers)
Surgery has no routine role except rare highly selected cases (solitary brain metastasis + early primary = 5-year survival ~10-15%)

TNM Classification Summary

T Stage	Meaning
T3	Invades chest wall (including ribs), parietal pleura - potentially resectable
T4	Invades vertebral body, subclavian vessels, brachial plexus (C8 or above) - technically unresectable by standard criteria
N0/N1	No or ipsilateral hilar nodal involvement - surgery may be attempted
N2/N3	Mediastinal/contralateral nodal involvement - surgery generally not indicated, prognosis very poor
M0	No distant metastasis - localized disease
M1	Distant metastasis - metastatic disease

Treatment by Stage

Non-Metastatic (Stage IIB/IIIA - the "curative" pathway)

Mediastinoscopy to confirm N0/N1 status (mandatory before surgery)
Induction chemoradiotherapy: cisplatin + etoposide x 2 cycles + concurrent 45 Gy radiation
Surgery: en bloc resection via thoracotomy - lobectomy + chest wall resection (ribs, lower brachial plexus trunk, stellate ganglion), sometimes subclavian vessel reconstruction
Chest wall reconstruction with Gore-Tex for defects >2 rib segments

Results from the North America Intergroup Trial:

Pathologic complete response or minimal residual disease: 66%
Overall 5-year survival: 44%
5-year survival with complete resection: 54%

Stage IIIB (T4 or N2/N3)

Concurrent chemoradiotherapy without surgery
Definitive radiation doses (60-66 Gy)
5-year survival drops substantially

Metastatic (Stage IV)

Systemic chemotherapy (platinum-based doublets for NSCLC)
Targeted therapy if driver mutations present (EGFR, ALK, ROS1, etc.)
Immunotherapy (checkpoint inhibitors) where applicable
Surgery is not standard; palliative intent

Key Prognostic Factors (Worse Prognosis)

N1 or N2 nodal involvement
Incomplete resection (R1/R2)
Vertebral body involvement
Supraclavicular (N3) involvement
Weight loss
Stage IV disease at diagnosis

Summary Table

Feature	Non-Metastatic	Metastatic
Stage	IIB to IIIB (M0)	IV (M1)
Prevalence at dx	~50-67% of all cases	~33-50% of all cases
Treatment intent	Curative (chemo-RT + surgery)	Palliative (systemic therapy)
5-year survival	44-54% (complete resection)	<5%
Most common metastatic site	-	Brain

Sources:

Murray & Nadel's Textbook of Respiratory Medicine, Vol. 2 - Superior Sulcus Tumors and Pancoast Syndrome
Schwartz's Principles of Surgery, 11th Ed. - Surgery for Management of Pancoast's Tumor
Robbins & Kumar Basic Pathology - Lung Carcinoma
Recent systematic review on therapeutic modalities: Langer et al., Lung Cancer 2025 (PMID 40651130)

This is a shared conversation. Sign in to Orris to start your own chat.